AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 15 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - CancerVax, which has been used in the immunotherapy of melanoma, may also be useful against colon cancer, researchers in California have found.
Colon cancer patients with advanced disease show immune responses to the vaccine that correlate with overall survival, said N. Habal and colleagues at the John Wayne Cancer Institute, Santa Monica.
"Because the various antigens expressed on the vaccine are common to colon adenocarcinoma cells, we examined the survival impact of immune responses elicited by CancerVax in patients with advanced colon cancer refractory to standard therapy," said Habal and coworkers.
They administered CancerVax to 27 patients with stage IV colorectal adenocarcinoma, plus bacillus Calmette-Guerin (BCG) for the first two weeks, and then measured serum immunoglobulin (Ig) G and IgM against TA90 (a 90-kD immunogen common to colon cancer and CancerVax cells) and against purified protein derivative (PPD), a nontumor control antigen.
Cellular immune responses were evaluated by delayed-type hypersensitivity (DTH) reaction to vaccine cells and to PPD for a mean follow-up time of 17.5 months.
The subjects showed a significant increase in anti-TA90 IgG and IgM titers and in DTH response to vaccine cells, though humoral and skin responses to TA90 did not correlate with responses to PPD, the authors reported.
Source: HighBeam Research, CancerVax Immune Responses Correlate With Improved Survival.